LIPO News and Press, Lipella Pharmaceuticals Inc.

2025-09-24 07:58:36 ET More on Nasdaq Nasdaq: Fairly Valued For Steady Compounding Nasdaq, Inc. (NDAQ) Presents At Barclays 23rd Annual Global Financial Services Conference Transcript Nasdaq, Inc. 2025 Q2 - Results - Earnings Call Presentation SEC clears Cboe...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18 th are now available for online viewing. REGISTER AND VIEW PR...

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR. Individual investors, institutional i...

Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus PR Newswire PITTSBURGH , Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Co...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Lipella Pharmaceuticals Inc. (LIPO) is expected to report for Q2 2025

2025-06-25 18:00:32 ET CEO addresses shareholders with update on relisting efforts, pipeline progress, and financial stability The clinical-stage biotech company developing treatments for diseases with significant unmet medical need Lipella Pharmaceuticals Inc. (OTC: LIPO ), is ...

PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Ex...

PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearin...